Discovery of a drug candidate for GLIS3-associated diabetes

Discovery of a drug candidate for GLIS3-associated diabetes

GLIS3 mutations are associated with type 1, type 2, and neonatal diabetes. Here, the authors generate mono-hormonal glucose-responding pancreatic β-like cells in vitro and through a screen identify a drug that rescues pancreatic β-like cell death in GLIS3 mutants by inhibiting the abnormally activat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sadaf Amin, Brandoch Cook, Ting Zhou, Zaniar Ghazizadeh, Raphael Lis, Tuo Zhang, Mona Khalaj, Miguel Crespo, Manuradhi Perera, Jenny Zhaoying Xiang, Zengrong Zhu, Mark Tomishima, Chengyang Liu, Ali Naji, Todd Evans, Danwei Huangfu, Shuibing Chen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/c14e49f0fd174b1ebce0f8854fb56b94
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:GLIS3 mutations are associated with type 1, type 2, and neonatal diabetes. Here, the authors generate mono-hormonal glucose-responding pancreatic β-like cells in vitro and through a screen identify a drug that rescues pancreatic β-like cell death in GLIS3 mutants by inhibiting the abnormally activated TGFβ pathway.

Ejemplares similares